Literature DB >> 1535600

p21ras contributes to HIV-1 activation in T-cells.

C T Baldari1, G Macchia, A Massone, J L Telford.   

Abstract

Activation of T-cells infected by HIV-1 results in activation of long terminal repeat (LTR)-dependent viral transcription and ultimately the production of infectious virus. Although full T-cell activation requires a complex series of intracellular signals, including protein kinase C activation, calcium mobilisation, and less-well defined lymphokine-induced signals, the HIV-1 LTR can be activated by subsets of these signals. We have studied the interaction of these signals in the human lymphoma line, Jurkat, in activation of the HIV-1 LTR. The HIV promoter was induced by IL-1 and phorbol ester activation of PKC but not by a calcium ionophore. The constitutively active form of Ha-ras could replace phorbol ester stimulation of the HIV promoter and of a synthetic promoter containing NF kappa B binding sites.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535600     DOI: 10.1016/0014-5793(92)80633-r

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

Review 1.  T helper cell activation and human retroviral pathogenesis.

Authors:  K F Copeland; J L Heeney
Journal:  Microbiol Rev       Date:  1996-12

2.  Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist.

Authors:  G Poli; A L Kinter; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

3.  Ras oncogene enhances the production of a recombinant protein regulated by the cytomegalovirus promoter in BHK-21 cells.

Authors:  T Yano; K Teruya; S Shirahata; J Watanabe; K Osada; H Tachibana; H Ohashi; E H Kim; H Murakami
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

4.  Protein phosphatase 2A enhances activation of human immunodeficiency virus type 1 by phorbol myristate acetate.

Authors:  Neil E Faulkner; Brian R Lane; Paul J Bock; David M Markovitz
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.